Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen hopes for Invega approval for the holidays

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Johnson & Johnson subsidiary's NDA for the antipsychotic Invega (paliperidone extended-release) has a Dec. 20 user fee goal date, J&J said Nov. 10 after submitting a response to FDA's Sept. 29 "approvable" letter (1Pharmaceutical Approvals Monthly October 2006, In Brief)...

You may also be interested in...



J&J paliperidone ER "approvable"

Johnson & Johnson's extended-release schizophrenia agent paliperidone is "approvable" Sept. 29; J&J says it will "work quickly to resolve the agency's questions." Earlier in September, the company had indicated that it expected an approvable decision. J&J submitted the follow-on compound to its blockbuster atypical antipsychotic Risperdal (risperidone) in December 2005 (1Pharmaceutical Approvals Monthly December 2005, In Brief)...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel